

September 25, 1998, which claims right of priority under 35 U.S.C. § 120 to Application No. 08/316,439, filed September 30, 1994, now U.S. Patent No. 5,840,520, issued November 24, 1998, and which claims priority benefit under 35 U.S.C. §119(e) of provisional Application Nos. 60/060,153, filed September 26, 1997, 60/084,133, filed May 1, 1998, and 60/089,207, filed June 12, 1998, each of which is incorporated herein by reference in its entirety.

IN THE CLAIMS

Please add new claims:

41. (New) The vaccine of claim 17, wherein any one of the eight gene segments of the viral genome is replaced by a heterologous sequence.

42. (New) The vaccine of claim 41, wherein the gene segment is completely replaced by the heterologous sequence.

43. (New) The vaccine of claim 41, wherein the gene segment is partially replaced by the heterologous sequence.

44. (New) The vaccine of claim 41, wherein the gene segment is selected from the group consisting of L, M2-1, M2-2, NS1, NS2, and G.

45. (New) The vaccine of claim 41, wherein the gene segment is partially replaced by the heterologous sequence.

46. (New) The vaccine of claim 17, wherein the a heterologous sequence is inserted in one of the viral genes.

47. (New) The vaccine of claim 46, wherein translation of the heterologous sequence is initiated from an internal ribosome entry site.

48. (New) A vaccine of any one of claims 41-47, wherein the virus is attenuated.